AstraZeneca’s long-acting Strensiq follow-up efzimfotase alfa has hit the mark in children with rare disease HPP, but the data in adults is unclear.
Pharma’s dealmaking tear; Blackstone raises record fund; Xolair energizes allergy research; and more
Welcome back to Endpoints Weekly! They say March comes in like a lion and out like a lamb, but two pharma giants made a roar


